Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)
Masayoshi Miyawaki(Keio University), Kenzo Soejima(Keio University), Ryosuke Satomi(Tokyo Medical Center), Sohei Nakayama(Beth Israel Deaconess Medical Center), Makoto Nishino(Keio University), Tetsuo Tani(Keio University), Hidefumi Koh(Tachikawa Hospital), Shinnosuke Ikemura(Keio University), Keiko Ohgino(Keio University), Satoshi Yoda(Harvard University), Fumio Sakamaki(Keio University), Aoi Kuroda(Keio University), Kota Ishioka(Keio University), Ho Namkoong(Keio University), Morio Nakamura(Saiseikai Central Hospital), Tomoko Betsuyaku(Tokyo Medical University), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Ichiro Kawada(Keio University), Kengo Otsuka(Keio University), Katsuhiko Naoki(Broad Institute), Masaki Miyazaki(Suita Municipal Hospital), Takashi Sato(Kitasato University), Koichi Sayama(Beth Israel Deaconess Medical Center), Takeshi Terashima(Keio University)
Cited by 10
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565